03:48 PM EST - YM BioSciences Inc. : announced that the first U.S. patient has been enrolled in its Phase II randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. YM anticipates that patients will also begin to be enrolled in the near future in its trial in patients with NSCLC ineligible for curative treatment and who are being treated with radiotherapy palliatively. YM BioSciences Inc.
shares T.YM are trading even at $1.41.
